Department of Neurology, Yale School of Medicine, New Haven, CT, USA.
Department of Neurology, Yale School of Medicine, New Haven, CT, USA; Division of Neurocritical Care and Emergency Neurology, Yale School of Medicine, New Haven, CT, USA.
Med. 2022 Aug 12;3(8):519-520. doi: 10.1016/j.medj.2022.07.006.
The standard medical therapy for intravenous thrombolysis in patients with stroke presenting within 3 h is alteplase, a tissue plasminogen activator. Menon and colleagues assessed the non-inferiority, efficacy, and safety of tenecteplase, a modified version of alteplase, in patients with acute ischemic stroke presenting within 4.5 h of onset.
对于发病 3 小时内的静脉溶栓患者，标准的医学治疗是阿替普酶（一种组织型纤溶酶原激活物）。Menon 及其同事评估了替奈普酶（阿替普酶的改良版）在发病 4.5 小时内的急性缺血性脑卒中患者中的非劣效性、疗效和安全性。
